Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 76, Issue 6, Pages 1498-1510Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkab043
Keywords
-
Funding
- Fondo de Investigacion Sanitaria [PI15/00860, PI18/00860, PI17/01482, PI20/01212]
- Instituto de Salud Carlos III (ISCIII)
- Spanish Network of Research in Infectious Diseases (REIPI) [RD16/0016/0006]
- ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) 'A way of making Europe'
- Investigator Initiated Studies Program - by Merck Sharp and Dohme (MSD)
- Miguel SERVET II program (ISCIIISERGAS) [CPII18/00024]
- Rio Hortega program (ISCIII-SERGAS) [CM19/00219]
- FNPS
- Juan Rodes program (ISCIII-SERGAS) [JR18/00006]
- pFIS program (ISCIII) [PI17/01482]
- Xunta de Galicia [IN606A-2019/029, IN606B-2018/011]
- AECC grant
- [IN607A 2016/22]
Ask authors/readers for more resources
Imipenem/relebactam, colistin, and ceftazidime/avibactam were found to be the most active antimicrobials against carbapenemase-producing Enterobacterales in a Spanish nationwide collection. The most widely disseminated high-risk clones of these carbapenemase-producing Klebsiella pneumoniae in Spain were identified as ST11, ST147, ST392, ST15, and ST258/512. The combination of imipenem/relebactam was particularly effective against KPC-producing isolates.
Background: Imipenem/relebactam is a novel carbapenem/b-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives: To assess the in vitro activity of imipenem/relebactam against a Spanish nationwide collection of CPE by testing the susceptibility of these isolates to 16 widely used antimicrobials and to determine the underlying beta-lactamresistance mechanisms involved and the molecular epidemiology of carbapenemases in Spain. Materials and methods: Clinical CPE isolates (n = 401) collected for 2 months from 24 hospitals in Spain were tested. MIC50, MIC90 and susceptibility/resistance rates were interpreted in accordance with the EUCAST guidelines. b-Lactam resistance mechanisms and molecular epidemiology were characterized by WGS. Results: For all isolates, high rates of susceptibility to colistin (86.5%; MIC50/90 C = 0.12/8 mg/L), imipenem/relebactam (85.8%; MIC50/90 = 0.5/4 mg/L) and ceftazidime/avibactam (83.8%, MIC50/90 = 1/>= 256mg/L)were observed. The subgroups of isolates producing OXA-48-like (n = 305, 75.1%) and KPC-like enzymes (n = 44, 10.8%) were highly susceptible to ceftazidime/avibactam (97.7%, MIC50/90 = 1/2 mg/L) and imipenem/relebactam (100.0%, MIC50/90 = <= 0.25/1 mg/L), respectively. The most widely disseminated high-risk clones of carbapenemase-producing Klebsiella pneumoniae across Spain were found to be ST11, ST147, ST392 and ST15 (mostly associated with OXA-48) and ST258/512 (in all cases producing KPC). Conclusions: Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available